Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Shares Outstanding (2016 - 2026)

Integra Lifesciences Holdings' Shares Outstanding history spans 17 years, with the latest figure at $92.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 0.74% to $92.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $92.3 million, a 0.74% increase, with the full-year FY2025 number at $92.3 million, up 0.74% from a year prior.
  • Shares Outstanding hit $92.3 million in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $92.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for IART hit a ceiling of $92.3 million in Q2 2025 and a floor of $89.4 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $90.9 million across 5 years, with a median of $90.9 million in 2023.
  • Biggest five-year swings in Shares Outstanding: grew 0.32% in 2021 and later grew 0.98% in 2022.
  • Tracing IART's Shares Outstanding over 5 years: stood at $89.6 million in 2021, then increased by 0.98% to $90.5 million in 2022, then grew by 0.49% to $90.9 million in 2023, then increased by 0.76% to $91.6 million in 2024, then increased by 0.74% to $92.3 million in 2025.
  • Business Quant data shows Shares Outstanding for IART at $92.3 million in Q4 2025, $92.3 million in Q3 2025, and $92.3 million in Q2 2025.